Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72(2):338–44.

Article  PubMed  Google Scholar 

Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32.

Article  CAS  PubMed  Google Scholar 

Dalmartello M, La Vecchia C, Bertuccio P, Boffetta P, Levi F, Negri E, et al. European cancer mortality predictions for the year 2022 with focus on ovarian cancer. Ann Oncol. 2022;33(3):330–9.

Article  CAS  PubMed  Google Scholar 

Soler-González G, Sastre-Valera J, Viana-Alonso A, Aparicio-Urtasun J, García-Escobar I, Gómez-España MA, et al. Update on the management of elderly patients with colorectal cancer. Clin Transl Oncol. 2024;26(1):69–84.

Article  PubMed  Google Scholar 

Rosati G. Learning to care for the older people: an urgent need in the daily practice of oncologists. J Clin Med. 2022;11(11):3149.

Article  PubMed  PubMed Central  Google Scholar 

Aparicio T, Canoui-Poitrine F, Caillet P, François E, Cudennec T, Carola E, et al. Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG). Dig Liver Dis. 2020;52(5):493–505.

Article  CAS  PubMed  Google Scholar 

Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2015;26(3):463–76.

Article  CAS  PubMed  Google Scholar 

Rosati G, Cordio S, Reggiardo G, Aprile G, Butera A, Avallone A, et al. Oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer aged at least 75 years: a post-hoc subgroup analysis of three phase II trials. Cancers. 2019;11(4):578.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosati G, Cordio S, Bordonaro G, Caputo G, Novello G, Reggiardo G, et al. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Ann Oncol. 2010;21(4):781–6.

Article  CAS  PubMed  Google Scholar 

Vamvakas L, Matikas A, Karampeazis A, Hatzidaki D, Kakolyris S, Christophylakis C, et al. Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged > 70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG). BMC Cancer. 2014;14:277.

Article  PubMed  PubMed Central  Google Scholar 

Rosati G, Avallone A, Aprile G, Butera A, Reggiardo G, Bilancia D. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemother Pharmacol. 2013;71(1):257–64.

Article  CAS  PubMed  Google Scholar 

Petrioli R, Francini E, Cherri S, Torre P, Fiaschi AI, Miano ST, et al. Capecitabine plus oxaliplatin and bevacizumab, followed by maintenance treatment with capecitabine and bevacizumab for patients aged > 75 years with metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17(4):e663–9.

Article  PubMed  Google Scholar 

Munemoto Y, Kanda M, Ishibashi K, Hata T, Kobayashi M, Hasegawa J, et al. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. BMC Cancer. 2015;15:786.

Article  PubMed  PubMed Central  Google Scholar 

Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Vera R, et al. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. Br J Cancer. 2014;111(2):241–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kato A, Miyoshi N, Ohtsuru T, Sakai D, Hasegawa J, Nakata K, et al. A phase II study of dose-reductive XELOX plus bevacizumab in elderly or vulnerable patients with metastatic colorectal cancer (MCSGO-1202). Anticancer Res. 2022;42(4):1859–65.

Article  CAS  PubMed  Google Scholar 

Avallone A, Piccirillo MC, Nasti G, Rosati G, Carlomagno C, Di Gennaro E, et al. Effect of bevacizumab in combination with standard oxaliplatin-based regimens in patients with metastatic colorectal cancer: a randomized clinical trial. JAMA Netw Open. 2021;4(7): e2118475.

Article  PubMed  PubMed Central  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

Article  CAS  PubMed  Google Scholar 

García-Alfonso P, Díaz-Rubio E, Abad A, Carrato A, Massutí B, Ortiz-Morales MJ, et al. First-line biological agents plus chemotherapy in older patients with metastatic colorectal cancer: a retrospective pooled analysis. Drugs Aging. 2021;38(3):219–31.

Article  PubMed  PubMed Central  Google Scholar 

Aparicio T, Bouché O, Taieb J, Maillard E, Kirscher S, Etienne P-L, et al. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. Ann Oncol. 2018;29(1):133–8.

Article  CAS  PubMed  Google Scholar 

Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(11):1077–85.

Article  CAS  PubMed  Google Scholar 

Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol. 2012;23(6):1531–6.

Article  CAS  PubMed  Google Scholar 

Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377(9779):1749–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Landre T, Uzzan B, Nicolas P, Aparicio T, Zelek L, Mary F, et al. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer: a meta analysis. Int J Colorectal Dis. 2015;30(10):1305–10.

Article  PubMed  Google Scholar 

Nigri G, Petrucciani N, Ferla F, La Torre M, Aurello P, Ramacciato G. Neoadjuvant chemotherapy for resectable colorectal liver metastases: what is the evidence? Results of a systematic review of comparative studies. Surgeon. 2015;13(2):83–90.

Article  PubMed  Google Scholar 

Kumari S, Semira C, Lee M, Lee B, Wong R, et al. Resection of colorectal cancer liver metastases in older patients. ANZ J Surg. 2020;90(5):796–801.

Article  PubMed  Google Scholar 

Mowbray NG, Chin C, Duncan P, O’Reilly D, Kaposztas Z, et al. How successful is liver resection for colorectal cancer liver metastases in patients over 75 years old? Ann Hepatobiliary Pancreat Surg. 2021;25(1):18–24.

Article  PubMed  PubMed Central  Google Scholar 

Venderbosch S, Doornebal J, Teerenstra S, Lemmens W, Punt CJA, Koopman M. Outcome of first-line systemic treatment in elderly compared with younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncol. 2012;51(7):831–9.

Article  CAS  PubMed  Google Scholar 

Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr U-P. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol. 2010;136(5):737–43.

Article  CAS  PubMed  Google Scholar 

Zhao C, Li S, Liu Q. Meta-analysis of molecular targetted agents in the treatment of elderly patients with metastatic colorectal cancer: does the age matter? J Chemother. 2016;28(4):321–7.

Article  CAS  PubMed